MedTrace Logo

Study of DERMABOND ProPen in Closure of Colectomy Wounds

NCT00978133 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2018-04-18

No results posted yet for this study

Summary

2-octylcyanoacrylate (2-OCA) has been used extensively in clinical practice in trauma, plastic surgery, orthopaedic surgery, emergency medicine and paediatrics. Most studies on 2-OCA to date have focused on closure of short wounds, and only one has included closure of abdominal wounds in the context of general surgery. Here, the investigators will look at the results of closure of abdominal wounds in patients undergoing elective colectomies with 2-OCA, which is commercially available to us, versus closure with skin staples, which is the current standard technique of skin closure employed in the Department of Colorectal Surgery, Singapore General Hospital. The primary objective was to measure effectiveness of 2-OCA in 2 respects - the adequacy of wound healing and cosmesis, and the incidence of superficial wound infection.

Conditions

  • Wound

Interventions

PROCEDURE

Dermabond ProPen (2-octylcyanoacrylate)

Application of 2 layers of Dermabond to abdominal wounds after closure of deep layers

PROCEDURE

Skin closure with skin staples

Skin closure with skin staples

Sponsors & Collaborators

  • Singapore General Hospital

    lead OTHER

Principal Investigators

  • Julian KP Ong, FRCSEd · Singapore General Hospital

  • Kok-Sun Ho, FRCS · Singapore General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2007-05-31
Completion
2007-05-31

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00978133 on ClinicalTrials.gov